Australasian Journal of Dermatology最新文献

{"title":"Culturally Safe and Decentralised Care: Patient Experiences of a Dermatology Clinic Embedded in an Aboriginal and Torres Strait Islander Primary Health Care Service","authors":"Nikhil Dwivedi,&nbsp;Nicholas Van Rooij,&nbsp;Geoffrey Spurling,&nbsp;Claudette (Sissy) Tyson,&nbsp;Sonya Egert,&nbsp;Erin McMeniman,&nbsp;Noel Hayman","doi":"10.1111/ajd.70128","DOIUrl":"10.1111/ajd.70128","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Skin disease is a major cause of morbidity in Australia and a leading reason for primary care visits. Aboriginal and Torres Strait Islander peoples experience a disproportionate burden of skin conditions but face barriers to accessing culturally safe specialist services. This study described patient demographics, presentations and experiences at a new community-based dermatology clinic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A mixed-methods study was conducted at an urban Aboriginal and Torres Strait Islander primary health care dermatology clinic in South East Queensland. Retrospective analysis of medical records (March 2021–December 2023) examined demographics, attendance and diagnoses. Verbal semi-structured interviews were undertaken with patients to explore their experiences, and data were analysed thematically.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Across 338 encounters, 76% of patients identified as Aboriginal and/or Torres Strait Islander and 72% were female. Attendance was 55%. 27% had previously accessed specialist dermatology care. In this urban cohort, inflammatory dermatoses predominated, including atopic dermatitis (<i>n</i> = 26), acne (<i>n</i> = 15), chronic spontaneous urticaria (<i>n</i> = 12) and psoriasis (<i>n</i> = 12). This differs from existing literature in rural and remote settings where infectious dermatoses often predominate. Seventeen patients participated in interviews led by Aboriginal and Torres Strait Islander Research Officers. Participants valued the clinic's accessibility, shorter wait times compared with hospital services and culturally safe environment. Barriers included transport, scheduling challenges and medication costs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>A community-based, culturally tailored clinic was perceived by patients as more accessible, culturally safe and responsive to their needs. Supporting similar models may help close the gap in dermatological care and outcomes for Aboriginal and Torres Strait Islander peoples.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"294-300"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.70128","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147721594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Merkel Cell Carcinoma in Queensland: Treatment, Incidence and Outcomes Over a 10-Year Period (2012–2021)","authors":"Danny R. Youlden,&nbsp;Shabnam Gujadhur,&nbsp;Artika Nath,&nbsp;Phoebe Woodrow,&nbsp;Julie Moore,&nbsp;Wen Xu,&nbsp;Bryan H. Burmeister","doi":"10.1111/ajd.70136","DOIUrl":"10.1111/ajd.70136","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Merkel Cell Carcinoma (MCC) is a rare skin cancer with aggressive behaviour. We present results for incidence and outcomes of MCC in Queensland, a population having the highest rates of skin cancer worldwide.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data for patients diagnosed with MCC between 2012 and 2021 were obtained from the population-based Queensland Oncology Repository. The age-standardised incidence rate trend was assessed using Joinpoint regression. Five-year MCC-specific survival was estimated using the Kaplan–Meier method and factors independently associated with survival were determined from a Fine-Grey multivariable model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 1061 patients with MCC were included. Median age at diagnosis was 78 years, 68% were male and 27% were immunocompromised. Nearly all patients (94%) received treatment within 365 days of diagnosis, of whom 79% had surgery, 58% had radiotherapy and 15% had intravenous systemic therapy, either alone or in combination with other modalities. The average annual incidence rate was 1.89 per 100,000 population and remained stable over the study period (p_trend = 0.13). Over one-third (35%) of the study cohort developed recurrences within 5 years, with a median time to recurrence of 11 months. Five-year MCC-specific survival increased from 61% between 2012 and 2016 to 69% during 2017–2021 (<i>p</i> = 0.01). Older age at diagnosis, higher tumour stage, a greater number of co-morbidities and immunosuppression were significantly associated with poorer survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our results indicate that the incidence of MCC in Queensland has stabilised following a long period of rapid increases. MCC-specific survival is improving, mostly for more advanced tumours, which is likely attributable to increasing use of immunotherapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"e291-e298"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147810166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sun-Related Behaviours and Photoprotection Practices in an Australian Hospital Outpatient Setting: Findings From a Cross-Sectional Survey","authors":"Jessica McClatchy,&nbsp;Vanessa Tran,&nbsp;Vanessa Morgan,&nbsp;Celestine Wong","doi":"10.1111/ajd.70139","DOIUrl":"10.1111/ajd.70139","url":null,"abstract":"<p>This cross-sectional survey of 127 hospital outpatients assessed sun exposure behaviours and photoprotection practices. Photoprotection was inconsistent and often sub-optimal, including among high-risk individuals. Findings highlight the need for improved patient education and targeted counselling to promote comprehensive, guideline-based photoprotection.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"309-312"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.70139","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147925973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Could an Essential Medicines List Strengthen Access and Equity in Australian Dermatology?","authors":"Conor Larney,&nbsp;Peter Foley","doi":"10.1111/ajd.70127","DOIUrl":"10.1111/ajd.70127","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"323-324"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Retrospective Review of Real-World Patterns of Biologic Use in Dermatology Across Metropolitan, Regional and Rural Settings","authors":"N. Abeysekera,&nbsp;K. Sibanda,&nbsp;C. Park,&nbsp;J. Griffin,&nbsp;G. Wagner,&nbsp;L. Banney","doi":"10.1111/ajd.70141","DOIUrl":"10.1111/ajd.70141","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Biologic therapies have transformed the management of inflammatory dermatologic conditions, including atopic dermatitis, psoriasis, hidradenitis suppurativa, and chronic spontaneous urticaria. However, studies in Australia and abroad highlight reduced uptake in regional areas, underscoring the need to address inequities in access.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method(s)</h3>\u0000 \u0000 <p>A retrospective audit was performed of adult patients prescribed Pharmaceutical Benefits Scheme (PBS) subsidised biologics for severe atopic dermatitis, chronic plaque psoriasis, hidradenitis suppurativa, or chronic spontaneous urticaria between 1 January 2022 and 31 July 2025. Complete biologic treatment histories were collected for all identified patients, including prescriptions initiated before or continuing after the study period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 372 patients received PBS-subsidised biologic medications for severe atopic dermatitis (42.7%), chronic spontaneous urticaria (25.8%), chronic plaque psoriasis (22.0%), and hidradenitis suppurativa (9.4%). Approximately 17% of all patients lived in regional/remote areas (Modified Monash Model [MMM] 3–5). Dupilumab (<i>n</i> = 159) and omalizumab (<i>n</i> = 96) were the most commonly prescribed first-line biologics overall. While wait times for appointments and biologic initiation were comparable across rurality classifications (median 72–77 days to first appointment, 226–304 days to first biologic), patients from MMM 3–5 regions faced significantly higher costs per appointment (MMM 3–5 $110, MMM 2 $53 and MMM 1 $36).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study highlights regional disparities in biologic therapy access within an Australian tertiary dermatology service. Addressing these inequities is vital to achieving equitable and sustainable dermatologic care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"e282-e290"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147980407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of IL-4Rα Inhibitors for Atopic Dermatitis: A Systematic Review and Meta Analysis of Randomised Controlled Trials","authors":"Ana Carolina Putini Vieira,&nbsp;Ellen de Freitas Rezende,&nbsp;Ana Carolina Ventura Santana de Jesus,&nbsp;Arianne Costa Baquião","doi":"10.1111/ajd.70138","DOIUrl":"10.1111/ajd.70138","url":null,"abstract":"<div>\u0000 \u0000 <p>Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting over 200 million people globally. Emerging IL-4Rα–targeted monoclonal antibodies have demonstrated strong efficacy and safety in clinical trials, warranting comparison with dupilumab, the current systemic standard. This meta-analysis synthesises available evidence on their efficacy and safety. PubMed, Embase and Cochrane Library were systematically searched in April 2025 for randomised controlled trials (RCTs) comparing IL-4Rα–targeting monoclonal antibodies versus placebo in moderate-to-severe AD, with EASI-75 as the primary outcome. Non-RCTs and trials using concomitant corticosteroids were excluded. Risk of bias was assessed using the Cochrane RoB-2 tool. Analyses were performed in R (v4.5.0), with heterogeneity evaluated by Cochran Q and <i>I</i>² statistics. Nineteen RCTs comprising 4465 patients met inclusion criteria. At week 16, IL-4Rα inhibitors showed sustained efficacy across EASI-50/75/90, IGA 0/1 and pruritus reduction. Dupilumab remained the most validated agent, with durable effects, low heterogeneity and favourable safety. Among novel biologics, stapokibart and rademikibart demonstrated the most promising results, achieving superior EASI-90 and ≥ 4-point PP-NRS responses: stapokibart (OR 4.94; 95% CI 3.20–7.61) and rademikibart (OR 4.61; 95% CI 1.68–12.65), though the latter showed higher odds of adverse events. Other agents (MG-K10, GR1802, 611, AK120) provided encouraging but limited data. IL-4Rα inhibitors represent effective and safe therapies for moderate-to-severe AD. Dupilumab remains the reference standard, while stapokibart and rademikibart emerge as promising next-generation options. Further large, long-term, head-to-head RCTs are warranted to confirm their comparative performance.</p>\u0000 <p><b>PROSPERO Registration:</b> CRD420251129343.</p>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"e269-e281"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147873226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alopecia Areata Prevalence in Australia: Insights From a Nationally Representative Cross-Sectional Survey Study","authors":"Rodney Sinclair,&nbsp;Samantha Eisman,&nbsp;Leona Yip,&nbsp;Maureen Hitschfeld,&nbsp;Anna Williamson,&nbsp;Giles Stratton,&nbsp;Christoph Lohan,&nbsp;Carol M. Y. Lee,&nbsp;Komal Kapoor,&nbsp;Candida da Fonseca Pereira","doi":"10.1111/ajd.70137","DOIUrl":"10.1111/ajd.70137","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background/Objectives</h3>\u0000 \u0000 <p>To estimate the lifetime and point prevalence of alopecia areata (AA) among Australians aged ≥ 15 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cross-sectional survey was conducted from August to September 2024 in a quota-balanced sample of the Australian population, aged ≥ 12 years (exploratory objective included participants aged 12–14 years). Participants completed the Alopecia Assessment Tool (ALTO) to identify AA. Participants with AA completed the Scalp Hair Assessment Patient-Reported Outcome to assess hair loss and a questionnaire on hair loss experience. Lifetime prevalence was calculated as the proportion of participants with AA per the ALTO, and point prevalence was calculated as the proportion of participants with AA per the ALTO and current scalp hair loss.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 8,256 participants, 194 had potential AA, and of those, 188 were aged ≥ 15 years. The lifetime prevalence (95% CI) of AA among those aged ≥ 15 years ranged from 1.2% (1.08–1.32) to 2.3% (2.13–2.47), with a point prevalence (95% CI) of 0.9% (0.79–1.01) to 1.4% (1.27–1.53). Of 194 participants with potential AA, 125 had healthcare provider (HCP)-diagnosed AA and 69 had self-diagnosed AA. More self-diagnosed participants had active hair loss than HCP-diagnosed participants. Thirty-nine HCP-diagnosed participants (31.2%) were not using any treatment/management approach, and of those, 23.1% were unaware of treatment/management options. Most self-diagnosed participants were using shampoos/conditioners recommended for hair loss (62.3%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>There is a need for improved AA education in Australia to increase awareness, given that approximately 36% of participants were self-diagnosed and 31% of HCP-diagnosed participants were not using treatment or a management approach.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"270-279"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.70137","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147866571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Utility of Artificial Intelligence in Dermatology Training and Practice: A National, Cross-Sectional Study","authors":"Samuel Morriss,&nbsp;Andrew Awad,&nbsp;Vanessa Morgan,&nbsp;Celestine Wong","doi":"10.1111/ajd.70091","DOIUrl":"10.1111/ajd.70091","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background/Objectives</h3>\u0000 \u0000 <p>Artificial intelligence (AI) is increasingly relevant to dermatology, yet clinical integration depends on workforce readiness. While the technical performance of AI tools is well described, the perspectives of dermatology trainees, who will shape future adoption, are less well understood. The objective of this study was to investigate Australian dermatology trainees' knowledge, utilisation, and perceptions of AI, and to identify barriers to implementation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A national, cross-sectional electronic survey was distributed to all Australian dermatology trainees (<i>n</i> = 118) enrolled with the Australasian College of Dermatologists between February 2025 and June 2025. Outcomes included self-reported familiarity with and use of AI tools, perceived utility across clinical and non-clinical tasks, and perceived barriers to integration.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Sixty-eight trainees responded (57.6%). Most trainees (81.4%) agreed that AI is likely to become an important tool in dermatology over the next 5–10 years. However, 69.1% reported no formal training. 32.4% had used AI tools, most commonly general-purpose generative AI, with use primarily informal and focused on educational, research, and administrative tasks rather than direct patient care. Commonly reported barriers included legal and ethical considerations (60.3%), concerns regarding reliability (54.4%), and limited training or knowledge (52.9%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Australian dermatology trainees express cautious optimism about AI, recognising its potential while identifying practical, educational, and governance-related challenges. Current use is limited and largely non-clinical, reflecting early-stage adoption. These findings highlight opportunities for structured AI literacy and education to support future integration as evidence, governance frameworks, and clinical applications continue to evolve.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"e314-e320"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.70091","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147466783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secukinumab in Hidradenitis Suppurativa With Concomitant Systemic Lupus Erythematosus and Advanced Kidney Disease: A Case Series Exploring the Il-17 Skin–Kidney Axis","authors":"Francisco Javier Melgosa Ramos,&nbsp;Ramón García-Ruiz,&nbsp;Antonio Martorell","doi":"10.1111/ajd.70123","DOIUrl":"10.1111/ajd.70123","url":null,"abstract":"","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"313-315"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147637807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Treatment Resistant EGFR Inhibitor-Induced Papulopustular Exanthema With Isotretinoin and Dapsone","authors":"Ishana Dixit,&nbsp;Raquel Ruiz Araujo,&nbsp;Pablo Fernandez-Peñas","doi":"10.1111/ajd.70087","DOIUrl":"10.1111/ajd.70087","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background/Objectives</h3>\u0000 \u0000 <p>Epidermal growth factor receptor inhibitors (EGFRi) commonly cause papulopustular exanthemas that may compromise the success of cancer therapy. While tetracyclines are first-line treatment, data on alternative systemic agents for refractory cases remain limited. This study compares the effectiveness and tolerability of isotretinoin and dapsone for managing tetracycline-resistant EGFRi–induced papulopustular eruptions in a tertiary dermatology service.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective review was conducted of patients with EGFRi-induced papulopustular eruptions treated with isotretinoin or dapsone between 2018 and 2024. Clinical data included demographics, malignancy type, EGFRi agent, eruption severity, prior therapies, Physician's Global Assessment, treatment outcomes, time to best response, adverse events, and EGFRi dose modification. Group comparisons used one-way ANOVA and chi-square/Fisher's exact tests.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Sixteen patients were identified (8 isotretinoin, 8 dapsone). Baseline severity was higher in the isotretinoin group. Time to best response was shorter with isotretinoin (mean 14.9 weeks) than dapsone (21.0 weeks). Complete resolution occurred in 62.5% of isotretinoin-treated patients and 50% of dapsone-treated patients. Both agents were well tolerated, with only mild mucocutaneous effects in the isotretinoin group and mild anemia in one dapsone patient. Survival at follow-up was higher among patients who continued EGFRi (with or without dose reduction) than among those who ceased treatment. No significant differences were observed between isotretinoin and dapsone in EGFRi dose modification patterns or overall response rates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Both isotretinoin and dapsone are effective, well-tolerated options for managing tetracycline-resistant EGFRi-induced papulopustular eruptions. Isotretinoin showed a trend toward faster improvement, while ultimate response rates were similar. Maintaining EGFRi therapy, even at reduced doses, in conjunction with dermatology treatment was associated with superior dermatological outcomes and higher survival at follow-up compared with cessation of EGFRi treatment, highlighting the importance of proactive dermatologic intervention to support oncologic treatment continuity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"67 5","pages":"288-293"},"PeriodicalIF":1.6,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajd.70087","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}